Jefferies Group’s Ascendis Pharma A/S ASND Stock Holding History

Jefferies Group’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-45,000	Closed	-$5.18M	–	2693
2019 Q2	$5.18M	Buy	45,000 +22,500	+100%	+$2.69M	0.04%	458
2019 Q1	$2.65M	Buy	22,500 +16,100	+252%	+$1.41M	0.02%	758
2018 Q4	$401K	Buy	+6,400	New	+$402K	﹤0.01%	1549

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Jefferies Group's ASND Position: Q2 2022 in Review

Jefferies Group sold out of Ascendis Pharma A/S (ASND) in Q2 2022, closing a stake of 1,800 shares — an estimated $211K sold.

Jefferies Group first reported a position in ASND in Q1 2019 and held it in 3 quarters. The position peaked at $1.12M in Q2 2019. 168 funds tracked by Wall St. Rank hold ASND as of Q2 2022.

Jefferies Group reported no remaining Ascendis Pharma A/S position as of Q2 2022 after selling out during the quarter.
Jefferies Group sold 1,800 Ascendis Pharma A/S shares in Q2 2022, an estimated $211K.
Jefferies Group first reported a position in Ascendis Pharma A/S in Q1 2019 and held it in 3 quarters.
Jefferies Group's Ascendis Pharma A/S position peaked at $1.12M in Q2 2019.
168 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2022.

Based on Jefferies Group's 13F filing for Q2 2022, filed 15 Aug 2022.